Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-10-04

Clinical Trial Update: Nilotinib in the Treatment of Systemic Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial on nilotinib for systemic sclerosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nilotinib (nilotinib)

Snippet

Sponsor: Hospital for Special Surgery, New York | Conditions: Systemic Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2017-10-04